-
Nvidia Says Dynamo Can Make DeepSeek R1 30X Faster With Blackwell, Months After The AI Model Sparked Selloff Leading To A $600 Billion Drop In Its Market Cap (CORRECTED)
Wednesday, March 19, 2025 - 8:01am | 646Read More...Editor’s Note: The story has been corrected to reflect a $600 billion drop in Nvidia’s market cap. At the GTC 2025 conference in San Jose, Nvidia Corp. (NASDAQ:NVDA) announced that the company's newly released open-source software, Dynamo, can make China's DeepSeek R1 AI model 30 times...
-
Fintech Focus For September 11, 2020
Thursday, September 10, 2020 - 6:31pm | 2385Read More...Quote Of The Day: I find that the harder I work, the more luck I seem to have. - Thomas Jefferson Fintech Movers: There is a great industry need for automated corporate actions solutions, according to a survey by SIX conducted among leading global asset managers, wealth managers, custodians,...
-
Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
Thursday, January 19, 2017 - 1:29pm | 1018Read More...Verastem Inc (NASDAQ: VSTM) is a biopharmaceutical company that focuses on discovering and developing therapies for the treatment of patients with cancer. Verastem acquired a license agreement from Infinity Pharmaceuticals granting Verastem exclusive worldwide rights to develop and...
-
Infinity Pharma At Risk Of AbbVie 'Walking Away'
Wednesday, June 15, 2016 - 8:08am | 320Read More...Infinity Pharmaceuticals Inc. (NASDAQ: INFI) released the initial data for Duvelisib on June 15, which were below expectations. Morgan Stanley’s Matthew Harrison downgraded the rating on the company from Overweight to Equal Weight, while lowering the price target from $11 to $1. Harrison...
